1. iScience. 2023 Oct 27;26(12):108294. doi: 10.1016/j.isci.2023.108294. 
eCollection 2023 Dec 15.

An ivermectin - atorvastatin combination impairs nuclear transport inhibiting 
dengue infection in vitro and in vivo.

Palacios-Rápalo SN(1), Farfan-Morales CN(1)(2), Cordero-Rivera CD(1), De 
Jesús-González LA(1)(3), Reyes-Ruiz JM(4)(5), Meraz-Ríos MA(6), Del Ángel RM(1).

Author information:
(1)Department of Infectomics and Molecular Pathogenesis, Center for Research and 
Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico.
(2)Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana (UAM), 
Unidad Cuajimalpa, Ciudad de México 05348, México.
(3)Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro 
Social, Zacatecas, Zacatecas, México.
(4)Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro 
Médico Nacional "Adolfo Ruiz Cortines", Instituto Mexicano del Seguro Social 
(IMSS), Veracruz 91897, México.
(5)Facultad de Medicina, Región Veracruz, Universidad Veracruzana (UV), Veracruz 
91700, México.
(6)Department of Molecular Biomedicine, Center for Research and Advanced Studies 
(CINVESTAV-IPN), Mexico City 07360, Mexico.

Dengue virus (DENV) uses cellular nuclear transport machinery to import some 
proteins into the nucleus. Recently, the non-structural protein 3 (NS3) of DENV 
was localized in the nucleus of infected cells; however, its nuclear import 
mechanism is still unknown. In this study, we demonstrate that Ivermectin (IVM) 
inhibits the nuclear localization of NS3 through the inhibition of the Importin 
α/β1 pathway. We also report that Atorvastatin (ATV) can modulate the nuclear 
transport of NS3 protease and NS5 polymerase of DENV-2. On the other hand, we 
found that IVM and ATV treatments reduce the alteration of nuclear pore complex 
(NPC) proteins, and an IVM+ATV combination reduced DENV infection both in vitro 
and in vivo. Hence, we conclude that ATV transport inhibition is an additional 
antiviral effect of this drug, suggesting a potential anti-DENV therapy in 
combination with IVM.

© 2023 The Author(s).

DOI: 10.1016/j.isci.2023.108294
PMCID: PMC10682259
PMID: 38034354

Conflict of interest statement: The authors declare no competing interests.